Evidence map›Paper›PMID 40973878›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Unraveling the role of specificity protein 1 in gliomas: pathophysiology and clinical implications.

Aida Naseri, Sepideh Razi, Nima Rezaei

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aida NaseriCancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Sepideh RaziCancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Nima RezaeiResearch Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Dr Qarib St, Keshavarz Blvd, Tehran, 14194, Iran. rezaei_nima@tums.ac.ir.ORCID http://orcid.org/0000-0002-3836-1827

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas present a significant challenge to modern medicine as some of the most diverse and malignant brain tumors. Despite considerable developments in curative measures, the prognosis remains unsatisfactory. A prime reason is that much is obscured about the genetic regulation of glioma pathogenesis. In recent years, specificity protein 1 (Sp1) has been recognized as a central transcription factor that promotes gliomagenesis. Sp1, which is overexpressed in glioma tissues, modulates gene transcription by targeting GC boxes through its zinc finger motifs. As a result, it can influence tumor formation, proliferation, invasion, and distant migration. The present review summarizes the structure, function, and regulation of Sp1. Furthermore, this study elucidates the underlying mechanism by which Sp1 interacts with signaling pathways to fuel tumor growth and chemoresistance. Finally, the current state of Sp1's clinical implications is outlined. These findings reveal the potential benefits of Sp1 as a therapeutic target and diagnostic tool, laying the foundation for future studies.

Indexed as

Brain NeoplasmsGliomaSp1 Transcription FactorAnimalsGene Expression Regulation, NeoplasticHumansSignal TransductionSP1 protein, humanSp1 Transcription FactorDiagnosesGliomasSp1Transcription factorTreatments

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.